An interventional study of Basal bolus insulin regimen in Diabetes Mellitus, Type 2 and Surgical Site Infection, sponsored by Abraham Hulst, MD, PhD. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-30.
Sponsored by Abraham Hulst, MD, PhD · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands — 28 open to participants now, 35 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Netherlands.
Among the 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands, this one is the 54th largest by planned enrollment of the 287 interventional ones that give a count, is one of 7 that started in 2025, is one of 99 with no phase, reaches primary completion later than 16 of the 34 other live ones, and was the 306th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →28 of the 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands are open now. Recruiting first, the newest first:
Maxima Medical Center · Sites in Netherlands
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, United States, Argentina and 16 more countries
Ages 18+
Isala · Sites in Netherlands
Ages 18+
AC Immune SA · Sites in Netherlands
Ages 18–75 · Healthy volunteers
Boehringer Ingelheim · Sites in Netherlands, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
326 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 109 · Phase 4 42
First in 1997; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,008 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 134 across the 287 interventional studies, 500 across the 39 observational. Of the 271 that completed or were terminated, 102 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 326 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Abraham Hulst, MD, PhD as lead sponsor.
Abraham Hulst, MD, PhD has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
9 of the studies in Diabetes Mellitus, Type 2 with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07463196AC Immune SAA Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors | 2026-12 |
| NCT06638567Abraham Hulst, MD, PhDPostoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections. | 2027-02 |
| NCT06735404Radboud University Medical CenterRAPIDE: The Feasibility of a Hybrid Care Model | 2027-03 |
| NCT06092476Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients | 2027-03-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol/L, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.
People with type 2 diabetes mellitus (PWT2D) are at increased risk of postoperative complications, especially surgical site infections (SSI).
The aim of this study to reduce SSI in PWT2D by implementing a proactive basal-bolus insulin regimen, compared to the reactive sliding scale regimen.
Adult patients with type 2 diabetes will be included in this multi-centre study.
Participants will receive a blind CGM, i.e. glucose data are masked for the participants and study team, from admission to the ward until discharge from the hospital. In addition, all participants are asked to complete several questionnaires 30 days after surgery.
Both regimens are currently used in clinical practice. Therefore, there is no additional trial-related burden depending on the intervention group allocation.
Participants will be monitored intensively and insulin dosage will be adjusted adequately to the measured glucose values by the treatment team.
The sample size is based on the SSI incidence rates. Wards are matched into pairs with comparable baseline incidence rates and in each pair, one ward will be randomly assigned to the intervention group; the other serves as the control. 18 wards from 8 participating centres are planned to be recruited, this translates to 9x2x56=1008 evaluable participants.
Keywords:
Diabetes mellitus, basal bolus, sliding scale, insulin regimen, surgical site infections
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients daily dose of insulin is calculated by their treatment team: In insulin naive patients 0.4-0.5IU/kg and 0,3IU/kg for patients aged\>70 or patients with impaired kidney function with an estimated glucose filtration rate \<60ml/min and 80-100% of own insulin for insulin-users. They receive half of this daily dose in long-acting insulin once a day. The other half of their total daily dose of insulin is provided as short-acting mealtime insulin. This short-acting insulin is administered before each meal. When needed, extra insulin can be given when needed. The measurements of blood glucose values are before each meal and at bedtime (4x/day).
Other: Basal bolus insulin regimen
Short-acting insulin is administered when blood glucose value is above 10,0 mmol/L according to a standardized dosage schedule. The measurements of blood glucose values are before each meal and at bedtime (4x/day).
Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
Surgical site infection
Incidence of postoperative surgical site infection, according to the criteria of the centres of disease control (CDC) for superficial incisional SSI, deep incisional SSI and organ / space SSI. SSIs will be measured at 30 days postoperatively via BLUEBELLE questionnaire, diagnosis by surgeon during standard postoperative visit at the surgery clinic 3-5 weeks after surgery and chart review.
Time frame: Until 30 days after surgery
Postoperative hospital-acquired infections (non-SSI)
Incidence of hospital-acquired infections, other than surgical site infections
Time frame: Recorded at 30 days postoperatively
Length of stay in the hospital (LoS-Hos)
Length of stay in the hospital, measured in days from admission to discharge from the hospital.
Time frame: Recorded at 30 days postoperatively
Hospital readmission
Rate of hospital readmissions within 30 days after surgery
Time frame: Recorded 30 days postoperatively
Days at home (DAH30)
Patient-reported number of days at home after surgery, between 0 and 30.
Time frame: Recorded 30 days postoperatively
Postoperative disability
Patient-reported level of disability 30 days after surgery, using the WHODAS-2.0 questionnaire. Summarized in a score between 0-100.
Time frame: Recorded 30 days postoperatively
Quality of life (QoL) after surgery
Patient-reported health-related quality of life 30 days after surgery, using the EuroQol 5D5L questionnaire, summarized in a score between 0 and 1.
Time frame: Recorded 30 days postoperatively
Glucose 2
Incidence of grade 2 hypoglycemia, a blood glucose below 3.0mmol/L.
Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.
Glucose 3
Incidence of grade 1 hyperglycemia, a blood glucose above 10.0mmol/L.
Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.
Glucose 4
Incidence of grade 2 hyperglycemia, a blood glucose above 14.0mmol/L.
Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.
CGM1
Percentage of time within glycaemic target range (3.9-10.0 mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).
Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.
CGM2
Percentage of time below glycaemic target range (\<3.9mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).
Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.
CGM3
Percentage of time above glycaemic target range (\>10.0mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).
Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.
Cost-effectiveness 1
The cost-effectiveness of the basal bolus insulin regimen compared to the sliding scale regimen, considering the costs per prevented of SSI in a cost-effectiveness analysis.
Time frame: Until 30 days after surgery
Cost-effectiveness 2
The number of quality adjusted life years (QALYs) gained after a cost-utility analysis.
Time frame: Up to 30 days after surgery.
Protocol adherence
The adherence to the protocol until discharge from the hospital
Time frame: During the hospital stay, until discharge
Plan to share: Yes — Complete data collection methods and results will be shared with other researchers upon a formal request made to the principal investigator including a detailed motivation for the request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: One year after reviewed publication of the primary results
Access criteria: Official request to the principal investigator
Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 25 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.